Business

Announcement on Voluntary Disclosure of the Initiation of Phase I Clinical Trial of the Adsorbed Acellular Pertussis (Component), Diphtheria and Tetanus, Haemophilus influenzae Type b (Conjugate) – Meningococcal ACYW-135 (Conjugate) Combination Vaccine and the Completion of Enrollment of the First Subject

Announcement on Voluntary Disclosure of the Initiation of Phase I Clinical Trial of the Adsorbed Acellular Pertussis (Component), Diphtheria and Tetanus, Haemophilus influenzae Type b (Conjugate) – Meningococcal ACYW-135 (Conjugate) Combination Vaccine and the Completion of Enrollment of the First Subject

articleCansino Biologics, Inc. Class ADecember 19, 20255/news/announcement-on-voluntary-disclosure-of-the-initiation-of-phase-i-clinical-trial-of-the-adsorbed-acellular-pertussis-component-diphtheria-and-tetanus-haemophilus-influenzae-type-b-conjugate-meningococcal-acyw-135-conjugate-combination-vaccine-and-the-completion-of-enrollment-of-the-first-subject
Announcement on Voluntary Disclosure of the Initiation of Phase I Clinical Trial of the Adsorbed Acellular Pertussis (Component), Diphtheria and Tetanus, Haemophilus influenzae Type b (Conjugate) – Meningococcal ACYW-135 (Conjugate) Combination Vaccine and the Completion of Enrollment of the First Subject

About this update from Cansino Biologics, Inc. Class A

Announcement on Voluntary Disclosure of the Initiation of Phase I Clinical Trial of the Adsorbed Acellular Pertussis (Component), Diphtheria and Tetanus, Haemophilus influenzae Type b (Conjugate) – Meningococcal ACYW-135 (Conjugate) Combination Vaccine and the Completion of Enrollment of the First Subject The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Cansino Biologics, Inc. Class A